Elizabeth L. Kramer, MD, PhD

Subacute TGF beta expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function. Kramer, EL; Hardie, WD; Madala, SK; Davidson, C; Clancy, JP. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2018; 315:L456-L465.

MicroRNA-145, Cystic Fibrosis Transmembrane Conductance Regulator, and Transforming Growth Factor-beta An (Un)tangled Regulatory Web. Kramer, EL; Clancy, JP. American Journal of Respiratory and Critical Care Medicine. 2018; 197:551-552.

Chronic beta 2AR stimulation limits CFTR activation in human airway epithelia. Brewington, JJ; Backstrom, J; Feldman, A; Kramer, EL; Moncivaiz, JO; Ostmann, AJ; Zhu, X; Lu, LJ; Clancy, JP. JCI insight. 2018; 3.

TGF beta as a therapeutic target in cystic fibrosis. Kramer, EL; Clancy, JP. Expert Opinion on Therapeutic Targets. 2018; 22:177-189.

Variable phenotype in a novel mutation in PHOX2B. Lombardo, RC; Kramer, E; Cnota, JF; Sawnani, H; Hopkin, RJ. American Journal of Medical Genetics, Part A. 2017; 173:1705-1709.

CFTR modulator therapies in pediatric cystic fibrosis: focus on ivacaftor. Kramer, EL; Clancy, JP. Expert Opinion on Orphan Drugs. 2016; 4:1033-1042.